Skip to main content
SpringerLink
Log in

Bone and Joint Disorders

  • Reference work entry
  • First Online:
Geriatric Medicine

  • 364 Accesses

Abstract

Musculoskeletal diseases often cause chronic pain and dysmobility and contribute considerably to the overall burden of disease in older adults. This chapter focuses on the commonest age-related bone and joint disorders: osteoporosis, osteoarthritis, gout, polymyalgia rheumatica, and giant cell arteritis. Osteoporosis is a systemic skeletal disease characterized by low bone strength and increased fracture risk. The diagnosis can be made after a low-energy fracture, by vertebral fracture assessment, bone densitometry, or based on clinical risk factors. Antiresorptive or osteoanabolic drugs can be used, while ensuring sufficient vitamin D levels and calcium intake. Osteoarthritis is a degenerative whole-joint disorder involving damaged cartilage, synovial inflammation, osteophyte formation, and subchondral bone sclerosis. Any joint may be involved but hand, hip, knee, shoulder, and spine osteoarthritis account for most disability. Physiotherapy and non-steroidal anti-inflammatory drugs are the mainstay of treatment. Joint prosthesis surgery remains the most effective option in late-stage hip, knee, or glenohumeral osteoarthritis. Gout is one of the commonest causes of acute mono- or oligoarthritis in older adults. Despite several effective treatment options for flares and urate-lowering therapies, gout remains poorly treated. Calcium pyrophosphate deposition disease has both similar and distinctive clinical features and treatment. Polymyalgia rheumatica and giant cell arteritis should be suspected in patients with sudden proximal limb pain and weakness, headache, jaw claudication, and/or visual disturbances. Diagnostic or treatment delay may lead to irreversible ischemic optic neuropathy. Extended glucocorticoid courses remain the cornerstone to treat these types of large vessel vasculitis, with attention to potential glucocorticoid side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163–96.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Jin Z, Wang D, Zhang H, Liang J, Feng X, Zhao J, Sun L. Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the Global Burden of Disease Study 2017. Ann Rheum Dis. 2020;79(8):1014–22.

    Article  PubMed  Google Scholar 

  3. Williams A, Kamper SJ, Wiggers JH, et al. Musculoskeletal conditions may increase the risk of chronic disease: a systematic review and meta-analysis of cohort studies. BMC Med. 2018;16:167.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726–33.

    Article  CAS  PubMed  Google Scholar 

  5. Almeida M, Laurent MR, Dubois V, Claessens F, O’Brien CA, Bouillon R, Vanderschueren D, Manolagas SC. Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev. 2017;97:135–87.

    Article  PubMed  Google Scholar 

  6. Bergström U, Björnstig U, Stenlund H, Jonsson H, Svensson O. Fracture mechanisms and fracture pattern in men and women aged 50 years and older: a study of a 12-year population-based injury register, Umea, Sweden. Osteoporos Int. 2008;19:1267–73.

    Article  PubMed  Google Scholar 

  7. Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393:364–76.

    Article  CAS  PubMed  Google Scholar 

  8. Riggs BL, Melton LJ 3rd, Robb RA, Camp JJ, Atkinson EJ, Oberg AL, Rouleau PA, McCollough CH, Khosla S, Bouxsein ML. Population-based analysis of the relationship of whole bone strength indices and fall-related loads to age- and sex-specific patterns of hip and wrist fractures. J Bone Miner Res. 2006;21:315–23.

    Article  PubMed  Google Scholar 

  9. Wainwright SA, Marshall LM, Ensrud KE, Cauley JA, Black DM, Hillier TA, Hochberg MC, Vogt MT, Orwoll ES, Study of Osteoporotic Fractures Research G. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab. 2005;90:2787–93.

    Article  CAS  PubMed  Google Scholar 

  10. Zebaze RM, Ghasem-Zadeh A, Bohte A, Iuliano-Burns S, Mirams M, Price RI, Mackie EJ, Seeman E. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet. 2010;375:1729–36.

    Article  PubMed  Google Scholar 

  11. van de Glind EM, Willems HC, Eslami S, Abu-Hanna A, Lems WF, Hooft L, de Rooij SE, Black DM, van Munster BC. Estimating the time to benefit for preventive drugs with the statistical process control method: an example with alendronate. Drugs Aging. 2016;33:347–53.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Vandenbroucke A, Luyten FP, Flamaing J, Gielen E. Pharmacological treatment of osteoporosis in the oldest old. Clin Interv Aging. 2017;12:1065–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med. 1992;327:1637–42.

    Article  CAS  PubMed  Google Scholar 

  14. Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick NM. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA Intern Med. 2015;175:913–21.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Papaioannou A, Ioannidis G, McArthur C, Hillier LM, Feldman S, Giangregorio L, Jaglal S, Jain R, Van der Horst ML, Adachi J. Preventing fractures in long-term care: translating recommendations to clinical practice. J Am Med Dir Assoc. 2021;22(1):36–42.

    Article  PubMed  Google Scholar 

  16. Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med. 2018;379:2407–16.

    Article  CAS  PubMed  Google Scholar 

  17. Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Bastin S, Gamble GD. Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women. J Bone Miner Res. 2020;35:20–7.

    Article  CAS  PubMed  Google Scholar 

  18. Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12:43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Shepstone L, Lenaghan E, Cooper C, et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet. 2018;391:741–7.

    Article  PubMed  Google Scholar 

  20. Maraka S, Kennel KA. Bisphosphonates for the prevention and treatment of osteoporosis. BMJ. 2015;351:h3783.

    Article  PubMed  Google Scholar 

  21. Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int. 2014;25:1439–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Laurent MR, Bravenboer N, Van Schoor NM, Bouillon R, Pettifor JM, Lips P. Rickets and osteomalacia. In: Bilezikian JP, editor. ASBMR primer on the metabolic bone diseases and disorders of mineral metabolism. 9th ed. Hoboken: Wiley Blackwell; 2018. p. 684–94.

    Chapter  Google Scholar 

  23. Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, Finkelstein JS, Endocrine S. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:1802–22.

    Article  CAS  PubMed  Google Scholar 

  24. Force USPST, Curry SJ, Krist AH, et al. Screening for osteoporosis to prevent fractures: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319:2521–31.

    Article  Google Scholar 

  25. Li G, Compston JE, Leslie WD, et al. Relationship between obesity and risk of major osteoporotic fracture in postmenopausal women: taking frailty into consideration. J Bone Miner Res. 2020;35(12):2355–62.

    Article  CAS  PubMed  Google Scholar 

  26. Villareal DT, Aguirre L, Gurney AB, Waters DL, Sinacore DR, Colombo E, Armamento-Villareal R, Qualls C. Aerobic or resistance exercise, or both, in dieting obese older adults. N Engl J Med. 2017;376:1943–55.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Lekamwasam S, Adachi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23:2257–76.

    Article  CAS  PubMed  Google Scholar 

  28. Aerssens J, Declerck K, Maeyaert B, Boonen S, Dequeker J. The effect of modifying dietary calcium intake pattern on the circadian rhythm of bone resorption. Calcif Tissue Int. 1999;65:34–40.

    Article  CAS  PubMed  Google Scholar 

  29. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354:669–83.

    Article  CAS  PubMed  Google Scholar 

  30. Bourke S, Bolland MJ, Grey A, Horne AM, Wattie DJ, Wong S, Gamble GD, Reid IR. The impact of dietary calcium intake and vitamin D status on the effects of zoledronate. Osteoporos Int. 2013;24:349–54.

    Article  CAS  PubMed  Google Scholar 

  31. Burt LA, Billington EO, Rose MS, Raymond DA, Hanley DA, Boyd SK. Effect of high-dose vitamin D supplementation on volumetric bone density and bone strength: a randomized clinical trial. JAMA. 2019;322:736–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, Staehelin HB, Meyer OW, Theiler R, Dick W, Willett WC, Egli A. Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. JAMA Intern Med. 2016;176:175–83.

    Article  PubMed  Google Scholar 

  33. Ferrari S, Libanati C, Lin CJF, et al. Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment. J Bone Miner Res. 2019;34:1033–40.

    Article  CAS  PubMed  Google Scholar 

  34. Bonnet N, Bourgoin L, Biver E, Douni E, Ferrari S. RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J Clin Invest. 2019;129:3214–23.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS, Dell RM, Adams AL. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med. 2020;383:743–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Cosman F, Peterson LR, Towler DA, Mitlak B, Wang Y, Cummings SR. Cardiovascular safety of abaloparatide in postmenopausal women with osteoporosis: analysis from the ACTIVE Phase 3 Trial. J Clin Endocrinol Metab. 2020;105(11):3384–95.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Leslie WD, Morin SN, Martineau P, Bryanton M, Lix LM. Association of bone density monitoring in routine clinical practice with anti-osteoporosis medication use and incident fractures: a matched cohort study. J Bone Miner Res. 2019;34:1808–14.

    Article  CAS  PubMed  Google Scholar 

  38. Gourlay ML, Fine JP, Preisser JS, May RC, Li C, Lui LY, Ransohoff DF, Cauley JA, Ensrud KE, Study of Osteoporotic Fractures Research G. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012;366:225–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Pereira D, Peleteiro B, Araujo J, Branco J, Santos RA, Ramos E. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthr Cartil. 2011;19:1270–85.

    Article  CAS  Google Scholar 

  40. Sun X, Zhen X, Hu X, Li Y, Gu S, Gu Y, Dong H. Osteoarthritis in the middle-aged and elderly in China: prevalence and influencing factors. Int J Environ Res Public Health. 2019;16(23):4701.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Styrkarsdottir U, Lund SH, Thorleifsson G, et al. Meta-analysis of Icelandic and UK data sets identifies missense variants in SMO, IL11, COL11A1 and 13 more new loci associated with osteoarthritis. Nat Genet. 2018;50:1681–7.

    Article  CAS  PubMed  Google Scholar 

  42. Schieker M, Conaghan PG, Mindeholm L, Praestgaard J, Solomon DH, Scotti C, Gram H, Thuren T, Roubenoff R, Ridker PM. Effects of interleukin-1beta inhibition on incident hip and knee replacement: exploratory analyses from a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2020;173(7):509–15.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Skou ST, Roos EM, Laursen MB, Rathleff MS, Arendt-Nielsen L, Simonsen O, Rasmussen S. A randomized, controlled trial of total knee replacement. N Engl J Med. 2015;373:1597–606.

    Article  CAS  PubMed  Google Scholar 

  44. Bennell KL, Nelligan R, Dobson F, et al. Effectiveness of an internet-delivered exercise and pain-coping skills training intervention for persons with chronic knee pain: a randomized trial. Ann Intern Med. 2017;166:453–62.

    Article  PubMed  Google Scholar 

  45. Qaseem A, McLean RM, O’Gurek D, Batur P, Lin K, Kansagara DL. Nonpharmacologic and pharmacologic management of acute pain from non-low back, musculoskeletal injuries in adults: a clinical guideline from the American College of Physicians and American Academy of Family Physicians. Ann Intern Med. 2020;173(9):739–48.

    Article  PubMed  Google Scholar 

  46. Machado GC, Maher CG, Ferreira PH, Pinheiro MB, Lin CW, Day RO, McLachlan AJ, Ferreira ML. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015;350:h1225.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, Kroenke K, Bair MJ, Noorbaloochi S. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE Randomized Clinical Trial. JAMA. 2018;319:872–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. McAlindon TE, LaValley MP, Harvey WF, Price LL, Driban JB, Zhang M, Ward RJ. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA. 2017;317:1967–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Deyle GD, Allen CS, Allison SC, Gill NW, Hando BR, Petersen EJ, Dusenberry DI, Rhon DI. Physical therapy versus glucocorticoid injection for osteoarthritis of the knee. N Engl J Med. 2020;382:1420–9.

    Article  CAS  PubMed  Google Scholar 

  50. Gregori D, Giacovelli G, Minto C, Barbetta B, Gualtieri F, Azzolina D, Vaghi P, Rovati LC. Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis. JAMA. 2018;320:2564–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Thorlund JB, Juhl CB, Roos EM, Lohmander LS. Arthroscopic surgery for degenerative knee: systematic review and meta-analysis of benefits and harms. BMJ. 2015;350:h2747.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16:380–90.

    Article  PubMed  Google Scholar 

  53. Kuo CF, Grainge MJ, See LC, Yu KH, Luo SF, Zhang W, Doherty M. Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Res Ther. 2015;17:13.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Zhang W, Doherty M, Bardin T, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011;70:563–70.

    Article  CAS  PubMed  Google Scholar 

  55. Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016;374:2575–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Fralick M, Chen SK, Patorno E, Kim SC. Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med. 2020;172:186–94.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388:2039–52.

    Article  CAS  PubMed  Google Scholar 

  58. Efstathiadou A, Gill D, McGrane F, Quinn T, Dawson J. Genetically determined uric acid and the risk of cardiovascular and neurovascular diseases: a mendelian randomization study of outcomes investigated in randomized trials. J Am Heart Assoc. 2019;8:e012738.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72:826–30.

    Article  PubMed  Google Scholar 

  60. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29–42.

    Article  CAS  PubMed  Google Scholar 

  61. Ornetti P, Vernier N, Fortunet C. Milwaukee shoulder syndrome affecting the elbow. Arthritis Rheum. 2013;65:538.

    Article  PubMed  Google Scholar 

  62. Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79:31–8.

    Article  PubMed  Google Scholar 

  63. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol. 2020;72:879–95.

    Article  PubMed  Google Scholar 

  64. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497–505.

    Article  CAS  PubMed  Google Scholar 

  65. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L, Investigators C. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378:1200–10.

    Article  CAS  PubMed  Google Scholar 

  66. Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, Becker MA. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-Based Study). Arthritis Rheumatol. 2017;69:203–12.

    Article  CAS  PubMed  Google Scholar 

  67. Zhang W, Doherty M, Pascual E, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011;70:571–5.

    Article  CAS  PubMed  Google Scholar 

  68. Doherty M, Jenkins W, Richardson H, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet. 2018;392:1403–12.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Crowson CS, Matteson EL. Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015. Semin Arthritis Rheum. 2017;47:253–6.

    Article  PubMed  PubMed Central  Google Scholar 

  70. van der Geest KSM, Sandovici M, Brouwer E, Mackie SL. Diagnostic accuracy of symptoms, physical signs, and laboratory tests for giant cell arteritis: a systematic review and meta-analysis. JAMA Intern Med. 2020;180(10):1295–304.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, Davis JM 3rd, Hunder GG, Therneau TM, Gabriel SE. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63:633–9.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Carmona FD, Vaglio A, Mackie SL, et al. A genome-wide association study identifies risk alleles in plasminogen and P4HA2 associated with giant cell arteritis. Am J Hum Genet. 2017;100:64–74.

    Article  CAS  PubMed  Google Scholar 

  73. Rhee RL, Grayson PC, Merkel PA, Tomasson G. Infections and the risk of incident giant cell arteritis: a population-based, case-control study. Ann Rheum Dis. 2017;76:1031–5.

    Article  CAS  PubMed  Google Scholar 

  74. Weyand CM, Goronzy JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371:50–7.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Gonzalez-Gay MA, Matteson EL, Castaneda S. Polymyalgia rheumatica. Lancet. 2017;390:1700–12.

    Article  PubMed  Google Scholar 

  76. Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum. 2012;64:943–54.

    Article  PubMed  Google Scholar 

  77. Karmacharya P, Donato AA, Aryal MR, et al. RS3PE revisited: a systematic review and meta-analysis of 331 cases. Clin Exp Rheumatol. 2016;34:404–15.

    PubMed  Google Scholar 

  78. Kermani TA, Schmidt J, Crowson CS, Ytterberg SR, Hunder GG, Matteson EL, Warrington KJ. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum. 2012;41:866–71.

    Article  CAS  PubMed  Google Scholar 

  79. Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015;74:1799–807.

    Article  CAS  PubMed  Google Scholar 

  80. Henckaerts L, Gheysens O, Vanderschueren S, Goffin K, Blockmans D. Use of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of polymyalgia rheumatica-A prospective study of 99 patients. Rheumatology (Oxford). 2018;57:1908–16.

    Article  CAS  PubMed  Google Scholar 

  81. van der Geest KSM, Borg F, Kayani A, Paap D, Gondo P, Schmidt W, Luqmani RA, Dasgupta B. Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia. Ann Rheum Dis. 2020;79:393–9.

    Article  PubMed  Google Scholar 

  82. Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA. 2016;315:2442–58.

    Article  CAS  PubMed  Google Scholar 

  83. Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018;77:636–43.

    Article  PubMed  Google Scholar 

  84. Sammel AM, Hsiao E, Schembri G, et al. Diagnostic accuracy of positron emission tomography/computed tomography of the head, neck, and chest for giant cell arteritis: a prospective, double-blind, cross-sectional study. Arthritis Rheumatol. 2019;71:1319–28.

    Article  PubMed  Google Scholar 

  85. Rubenstein E, Maldini C, Gonzalez-Chiappe S, Chevret S, Mahr A. Sensitivity of temporal artery biopsy in the diagnosis of giant cell arteritis: a systematic literature review and meta-analysis. Rheumatology (Oxford). 2020;59:1011–20.

    Article  PubMed  Google Scholar 

  86. Buttgereit F, Matteson EL, Dejaco C. Polymyalgia rheumatica and giant cell arteritis. JAMA. 2020;324(10):993–4.

    Article  PubMed  Google Scholar 

  87. Mainbourg S, Addario A, Samson M, et al. Prevalence of giant cell arteritis relapse in patients treated with glucocorticoids: a meta-analysis. Arthritis Care Res (Hoboken). 2020;72:838–49.

    Article  CAS  PubMed  Google Scholar 

  88. Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317–28.

    Article  CAS  PubMed  Google Scholar 

  89. Adler S, Reichenbach S, Gloor A, Yerly D, Cullmann JL, Villiger PM. Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. Rheumatology (Oxford). 2019;58:1639–43.

    Article  CAS  PubMed  Google Scholar 

  90. Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 2017;69:837–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Paget J. On a form of chronic inflammation of bones (Osteitis deformans). Med Chir Trans. 1877;60:37–64.9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Geriatrics Department, Imelda Hospital, Bonheiden, Belgium

    Michaël R. Laurent

  2. Centre for Metabolic Bone Diseases, University Hospitals Leuven, Leuven, Belgium

    Michaël R. Laurent

Authors
  1. Michaël R. Laurent
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michaël R. Laurent .

Editor information

Editors and Affiliations

  1. California Association of Long Term Care Medicine, Newbury Park, CA, USA

    Michael R. Wasserman

  2. Betty Irene Moore School of Nursing, University of California, Davis, Sacramento, CA, USA

    Debra Bakerjian

  3. Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA

    Sunny Linnebur

  4. Division of Geriatrics, SUNY Upstate Medical University, Syracuse, NY, USA

    Sharon Brangman

  5. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

    Matteo Cesari

  6. Section of Geriatric Medicine, Division of Internal Medicine, Department of Medicine, Cedars-Sinai, Beverly Hills, CA, USA

    Sonja Rosen

Section Editor information

  1. California Association of Long Term Care Medicine, Newbury Park, California, USA

    Michael R. Wasserman M.D., CMD

  2. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

    Matteo Cesari MD, PhD

  3. Geriatric Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

    Matteo Cesari MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2024 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Laurent, M.R. (2024). Bone and Joint Disorders. In: Wasserman, M.R., Bakerjian, D., Linnebur, S., Brangman, S., Cesari, M., Rosen, S. (eds) Geriatric Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-74720-6_61

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-74720-6_61

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-74719-0

  • Online ISBN: 978-3-030-74720-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation